Rare Disease Framework Initiative launched; public meeting October 28

What changed

FDA opened a process to build a "holistic, fit-for-purpose framework" for rare-disease drug development and review. It made six commitments, among them:

• clearer, more predictable decisions;
• patient input at defined milestones;
• risk-based chemistry, manufacturing and controls review and inspections;
• novel statistical methods.

Possible outputs named by FDA: new or revised guidance, regulatory revisions, training and organizational change.

Naming note

This is not the separate CDER/CBER Rare Disease Evidence Principles (RDEP) process, which FDA describes as "a proposed process to facilitate the approval of drugs to treat rare diseases".

Next decision points

• Public meeting October 28, 2026, 1:00–5:00 p.m. ET, hybrid (FDA White Oak and Zoom; Reagan-Udall Foundation).
• Comments due December 11, 2026.

Sources

• FDA press release Rare Disease Framework Initiative Primary · 2026-10-14 · checked 2026-10-19
• FDA meeting page Oct 28 Primary · checked 2026-10-19
• Federal Register 2026-21142 Primary · 2026-10-16 · checked 2026-10-19
• FDA CDER/CBER Rare Disease Evidence Principles (RDEP) - distinct process Primary · checked 2026-10-20

Related on this site

• Policy §5
• Forecast F-04
• Reform (evidence proportionality)
• Records ledger

Register: the record store · record id fda-rare-disease-framework-initiative-2026-10-14 · SOURCE-VERIFIED · HUMAN REVIEW PENDING.